Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010232 | 1.00 | SLC1A1 (0.33) | SLC1A1NOS2NOS1NOS3ARG1 | |
| SCHEMBL6010239 | 0.78 | SLC1A1 (0.31) | SLC1A1NOS2NOS1NOS3ARG1 | |
| SCHEMBL3290225 | 0.77 | BHMT (0.37) | SLC1A1NOS2NOS1NOS3ARG1 | |
| SCHEMBL3290209 | 0.77 | BHMT (0.37) | SLC1A1NOS2NOS1NOS3ARG1 | |
| SCHEMBL6010163 | 0.75 | OR51E2 (0.39) | ALDH1A1 | |
| SCHEMBL6010151 | 0.75 | OR51E2 (0.39) | ALDH1A1 | |
| SCHEMBL6010225 | 0.75 | OR51E2 (0.35) | SLC1A1NOS2NOS1NOS3ARG1 | |
| Cystine SCHEMBL9615040 | 0.75 | PTGS1 (0.48) | SLC1A1NOS2NOS1NOS3ARG1 | |
| Cystine SCHEMBL9615032 | 0.75 | PTGS1 (0.48) | SLC1A1NOS2NOS1NOS3ARG1 | |
| SCHEMBL8159939 | 0.74 | SLC1A2 (0.40) | SLC1A1NOS2NOS1NOS3ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | SLC1A1 3047/4885NOS2 3333/4885NOS1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.